Lv31
350 积分 2023-01-12 加入
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C
6天前
已完结
Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies
5个月前
已完结
Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies
6个月前
已完结
皖公网安备34019202002308
